147 related articles for article (PubMed ID: 36693779)
21. A novel synthesis of a chlorophyll b-gold nanoconjugate used for enhancing photodynamic therapy: In vitro study.
Alexeree S; ElZorkany HE; Abdel-Salam Z; Harith MA
Photodiagnosis Photodyn Ther; 2021 Sep; 35():102444. PubMed ID: 34284147
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.
Shojaei Baghini S; Gardanova ZR; Abadi SAH; Zaman BA; İlhan A; Shomali N; Adili A; Moghaddar R; Yaseri AF
Cell Mol Biol Lett; 2022 May; 27(1):35. PubMed ID: 35508982
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9 Editing of Glia Maturation Factor Regulates Mitochondrial Dynamics by Attenuation of the NRF2/HO-1 Dependent Ferritin Activation in Glial Cells.
Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Kempuraj D; Dubova I; Saeed D; Zahoor H; Premkumar K; Zaheer S; Iyer S; Zaheer A
J Neuroimmune Pharmacol; 2019 Dec; 14(4):537-550. PubMed ID: 30810907
[TBL] [Abstract][Full Text] [Related]
24. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.
Wang SW; Gao C; Zheng YM; Yi L; Lu JC; Huang XY; Cai JB; Zhang PF; Cui YH; Ke AW
Mol Cancer; 2022 Feb; 21(1):57. PubMed ID: 35189910
[TBL] [Abstract][Full Text] [Related]
25. A Rationally Designed Semiconducting Polymer Brush for NIR-II Imaging-Guided Light-Triggered Remote Control of CRISPR/Cas9 Genome Editing.
Li L; Yang Z; Zhu S; He L; Fan W; Tang W; Zou J; Shen Z; Zhang M; Tang L; Dai Y; Niu G; Hu S; Chen X
Adv Mater; 2019 May; 31(21):e1901187. PubMed ID: 30957918
[TBL] [Abstract][Full Text] [Related]
26. Biomedical Platform Development of a Chlorophyll-Based Extract for Topic Photodynamic Therapy: Mechanical and Spectroscopic Properties.
Campanholi KDSS; Braga G; da Silva JB; da Rocha NL; de Francisco LMB; de Oliveira ÉL; Bruschi ML; de Castro-Hoshino LV; Sato F; Hioka N; Caetano W
Langmuir; 2018 Jul; 34(28):8230-8244. PubMed ID: 29933698
[TBL] [Abstract][Full Text] [Related]
27. Spatiotemporal Delivery of CRISPR/Cas9 Genome Editing Machinery Using Stimuli-Responsive Vehicles.
Cai W; Luo T; Mao L; Wang M
Angew Chem Int Ed Engl; 2021 Apr; 60(16):8596-8606. PubMed ID: 32385892
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
29. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
30. The power and the promise of CRISPR/Cas9 genome editing for clinical application with gene therapy.
Guo N; Liu JB; Li W; Ma YS; Fu D
J Adv Res; 2022 Sep; 40():135-152. PubMed ID: 36100322
[TBL] [Abstract][Full Text] [Related]
31. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
32. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Kim SM; Yang Y; Oh SJ; Hong Y; Seo M; Jang M
J Control Release; 2017 Nov; 266():8-16. PubMed ID: 28916446
[TBL] [Abstract][Full Text] [Related]
33. Tumor microenvironment based stimuli-responsive CRISPR/Cas delivery systems: A viable platform for interventional approaches.
Tang N; Ning Q; Wang Z; Tao Y; Zhao X; Tang S
Colloids Surf B Biointerfaces; 2022 Feb; 210():112257. PubMed ID: 34894597
[TBL] [Abstract][Full Text] [Related]
34. Conditional CRISPR-Cas Genome Editing in
Bahuguna S; Redhai S; Zhou J; Wang T; Port F; Boutros M
Cells; 2021 Nov; 10(11):. PubMed ID: 34831379
[TBL] [Abstract][Full Text] [Related]
35. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
[TBL] [Abstract][Full Text] [Related]
36. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
[TBL] [Abstract][Full Text] [Related]
37. Improved CRISPR/Cas9 gene editing by fluorescence activated cell sorting of green fluorescence protein tagged protoplasts.
Petersen BL; Möller SR; Mravec J; Jørgensen B; Christensen M; Liu Y; Wandall HH; Bennett EP; Yang Z
BMC Biotechnol; 2019 Jun; 19(1):36. PubMed ID: 31208390
[TBL] [Abstract][Full Text] [Related]
38. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
39. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy.
Zhang D; Wang G; Yu X; Wei T; Farbiak L; Johnson LT; Taylor AM; Xu J; Hong Y; Zhu H; Siegwart DJ
Nat Nanotechnol; 2022 Jul; 17(7):777-787. PubMed ID: 35551240
[TBL] [Abstract][Full Text] [Related]
40. PEGylated hydrazided gold nanorods for pH-triggered chemo/photodynamic/photothermal triple therapy of breast cancer.
Xu W; Qian J; Hou G; Wang Y; Wang J; Sun T; Ji L; Suo A; Yao Y
Acta Biomater; 2018 Dec; 82():171-183. PubMed ID: 30336271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
